Trading Signals: CHRS Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Tue. Oct. 10, 2023)(Coherus BioSciences Inc)
| CHRS latest price $27.9900 (-6.29%) ($26.9300 - $30.2200) on Mon. Aug. 24, 2015. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 2.69% (three month average) | | RSI | 50 | | Latest Price | $27.9900(-6.29%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | CHRS declines -3.4% a day on average for past five trading days. | | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | | Correlated ETFs | Broad market will support CHRS advance at 0% a week (0% probability)
XBI(47%) IBB(46%) IWO(44%) IWM(42%) IWN(38%) | | Factors Impacting CHRS price | CHRS will decline at least -1.345% in a week (0% probabilities).
VIXM(-15%) TLT(-6%) SHY(-5%) IGOV(-4%) UUP(-3%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.345% (StdDev 2.69%) | | Hourly BBV | 0 () | | Intraday Trend | -0.8% | | | | | |
|
| 5 Day Moving Average | $29.96(-6.58%) | | 10 Day Moving Average | $31.69(-11.68%) | | 20 Day Moving Average | $0(INF%) | | To recent high | -18.4% | | To recent low | 0% | | Market Cap | $1.997b | | | | | | |
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA. |